Article
Biochemistry & Molecular Biology
Qingkang Cao, Yuanyuan Chen
Summary: The study shows that m(6)A modification plays a significant role in the prognosis of pan-cancer and the formation of complex tumor microenvironment (TME). Through comprehensive analysis of RNA-seq data of different cancer types, two distinct m(6)A modification patterns were identified, which were closely associated with TME cell infiltration and overall patient survival. The study also presents the use of m6Ascore, based on the expression of m(6)A-related prognostic genes, as a successful predictor of patient survival.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Jiahua Chen, Bao Guo, Xiaojing Liu, Jing Zhang, Junhui Zhang, Yuan Fang, Suding Zhu, Bing Wei, Yunxia Cao, Lei Zhan
Summary: This review discusses the role of m(6)A in gynecologic cancers and summarizes the recent advancements in m(6)A modification in gynecologic cancers. It highlights the importance of m(6)A modification in tumor occurrence, metastasis, and treatment, and explores its potential as therapeutic targets and early diagnostic biomarkers.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Immunology
Liting Guo, Hui Yang, Chenfei Zhou, Yan Shi, Lei Huang, Jun Zhang
Summary: N6-methyladenosine (m(6)A) methylation is a common RNA modification in eukaryotic cells which has significant impact on tumor immune microenvironment, affecting the initiation and progression of various cancers. The association between m(6)A methylation and immune cells in tumor immunity is complex, potentially offering novel markers and targets for molecular pathological diagnosis and immunotherapy of cancers.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Bolun Zhou, Shugeng Gao
Summary: Recent studies have shown that m(6)A modification is closely associated with immune infiltration in early-stage lung adenocarcinoma (LUAD). By establishing m(6)A-predictive score, immunotherapeutic responses of patients can be predicted. Patients in different m(6)A gene-related clusters exhibit significant differences in immune characteristics and overall survival rates.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Meijing Zhang, Tianhang Luo, Yang Biao
Summary: This study systematically evaluated the modification patterns of 23 m6A regulatory factors in STAD. The results suggest that m6A modification may play a critical role in influencing immune cell infiltration in the TME of stomach adenocarcinoma. Additionally, higher m6A scores were associated with better prognosis, higher PD-L1 expression, and differences in high-frequency microsatellite instability subtype scores.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Jiakai Hou, Yunfei Wang, Leilei Shi, Yuan Chen, Chunyu Xu, Arash Saeedi, Ke Pan, Ritu Bohat, Nicholas A. Egan, Jodi A. McKenzie, Rina M. Mbofung, Leila J. Williams, Zhenhuang Yang, Ming Sun, Xiaofang Liang, Jordi Rodon Ahnert, Navin Varadarajan, Cassian Yee, Yiwen Chen, Patrick Hwu, Weiyi Peng
Summary: This study used genome-wide CRISPR immune screens to identify immunosuppressive mechanisms in non-responders to cancer immunotherapy and integrated the results with multi-omics clinical data to evaluate the role of tumor intrinsic factors in regulating two key steps of cancer immunotherapy. Two distinct types of immune resistance regulators were revealed, with PRMT1 and RIPK1 identified as potential therapeutic targets to improve the efficacy of immunotherapy. Targeting PRMT1 and RIPK1 sensitized tumors to T-cell killing and anti-PD-1/OX40 treatment, providing novel targets for rational immuno-oncology combinations.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Yong-fu Zhu, Shu-Jie Wang, Jie Zhou, Ye-han Sun, You-mou Chen, Jia Ma, Xing-xing Huo, Hang Song
Summary: This review focuses on the mutual regulation of m(6)A and coding and non-coding RNAs, introducing the molecular mechanism of m(6)A methylation involved in regulation and its role in cancer treatment using common female malignant tumors as an example.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Zhanmin Liang, Haokai Ye, Jiongming Ma, Zhen Wei, Yue Wang, Yuxin Zhang, Daiyun Huang, Bowen Song, Jia Meng, Daniel J. Rigden, Kunqi Chen
Summary: m(6)A-Atlas v2.0 is a valuable research tool that includes a large number of m(6)A sites and their functional annotations from different technologies and experimental conditions, to facilitate the study of this important RNA modification.
NUCLEIC ACIDS RESEARCH
(2023)
Review
Immunology
Ken Maes, Anna Mondino, Juan Jose Lasarte, Xabier Agirre, Karin Vanderkerken, Felipe Prosper, Karine Breckpot
Summary: Cancer cells can evade the immune system through epigenetic alterations, but epigenetic modulating agents have the potential to restore immunological fitness and overcome peripheral tolerance to transformed cells. By acting on both cancer cells and immune cells, EMAs represent interesting strategies for combinatorial therapies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Genetics & Heredity
Kun Fang, Hairong Qu, Jiapei Wang, Desheng Tang, Changsheng Yan, Jiamin Ma, Lei Gao
Summary: The study identified genetic mutations and dysregulation in m(6)A regulators in pancreatic cancer, leading to different prognosis, immune cell infiltration, and biological functions. A m(6)A scoring system was developed to show that high m(6)A scores are associated with poor clinical outcomes and more frequent mutations. Additionally, the study found that the m(6)A scores may be useful in predicting the response to immunotherapy.
FRONTIERS IN GENETICS
(2021)
Review
Oncology
Ze Zhang, Furong Liu, Wei Chen, Zhibin Liao, Wanguang Zhang, Bixiang Zhang, Huifang Liang, Liang Chu, Zhanguo Zhang
Summary: N6-methyladenosine modification plays an important role in tumor by regulating tumor immune escape, immune cell responses in the tumor microenvironment, and is closely associated with immunotherapy.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Nanfang Qu, Xiaotong Bo, Bin Li, Lei Ma, Feng Wang, Qinghua Zheng, Xuhua Xiao, Fengmei Huang, Yuanyuan Shi, Xuemei Zhang
Summary: Liver cancer ranks fifth in terms of incidence worldwide and is the third leading cause of cancer-related deaths. While advancements have been made in treatments such as surgical techniques and immunotherapy, the prognosis for liver cancer patients remains poor. Abnormal expression of m6A-related regulators in HCC has shown potential as diagnostic, prognostic, and therapeutic markers.
FRONTIERS IN ONCOLOGY
(2021)
Review
Cell Biology
Lei Zhan, Junhui Zhang, Suding Zhu, Xiaojing Liu, Jing Zhang, Wenyan Wang, Yijun Fan, Shiying Sun, Bing Wei, Yunxia Cao
Summary: Immunotherapy is effective in multiple cancers, but not all patients respond well to it. N-6-methyladenosine (m(6)A) RNA modification plays a key role in regulating immune cell function and may be crucial in turning cold tumors into hot ones.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Cell Biology
Jianhao Li, Weiwei Wang, Yubing Zhou, Liwen Liu, Guizhen Zhang, Kelei Guan, Xichun Cui, Xin Liu, Maoxin Huang, Guangying Cui, Ranran Sun
Summary: This study identified three distinct m6A modification clusters associated with clinical features, prognosis, and immune cell infiltration in hepatocellular carcinoma (HCC). High m6Ascore was closely related to tumor progression, poor prognosis, and lack of response to immunotherapy. Dysregulation of m6A regulators in HCC tissues served as predictors of poor prognosis, with YTHDF1 overexpression associated with low T cell infiltration.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Genetics & Heredity
Meng-Meng Zhang, Yi-Lin Lin, Wen-Feng Zeng, Yang Li, Yang Yang, Miao Liu, Ying-Jiang Ye, Ke-Wei Jiang, Shu Wang, Shan Wang
Summary: This study established a prognostic signature of BRCA based on m6A-related immune genes, which can effectively predict immune infiltration and prognosis, particularly in relation to immunotherapy. The low m6A-IS group demonstrated enhanced antigen presentation, improved immune checkpoint expression, and higher overall survival rates after treatment, indicating sensitivity to immunotherapy.
FRONTIERS IN GENETICS
(2021)
Article
Chemistry, Multidisciplinary
Xiao Guan, Guo-rong Dan, Yao Yang, Yan Ji, Wen-jing Lai, Fang-jie Wang, Meng Meng, Bang-hui Mo, Pei Huang, Ting-ting You, Ya-fei Deng, Liang Song, Wei Guo, Ping Yi, Jian-hua Yu, Yuan Gao, Wei-nian Shou, Bing-bo Chen, You-cai Deng, Xiao-hui Li
Summary: The study demonstrates that prenatal inflammatory exposure leads to multi-generational inheritance of hypertension in rat descendants, causing vascular remodeling and vasoconstrictor dysfunction. Furthermore, prenatal inflammatory exposure also results in global alteration of DNA methylome in the thoracic aorta of rat descendants.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Immunology
Qinglan Yang, Shuju Zhang, Shuting Wu, Baige Yao, Lili Wang, Yana Li, Hongyan Peng, Minghui Huang, Qinghua Bi, Peiwen Xiong, Liping Li, Yafei Deng, Youcai Deng
Summary: This study identified nafamostat mesylate (NM) as a selective stimulator of IFN-gamma production by NK cells, providing a new strategy for the prevention and treatment of infection or cancer in select populations.
IMMUNOLOGIC RESEARCH
(2022)
Article
Multidisciplinary Sciences
Shoubao Ma, Tingting Tang, Xiaojin Wu, Anthony G. Mansour, Ting Lu, Jianying Zhang, Li-Shu Wang, Michael A. Caligiuri, Jianhua Yu
Summary: PDGF-D mediates cell survival through the PDGFR beta signaling pathway without modulating effector functions of NK cells, providing new insights into the study of human NK cells.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Biotechnology & Applied Microbiology
Mengyuan Li, Yan Tang, Xinzhao Zuo, Silin Meng, Ping Yi
Summary: This study uncovered the relationship between G3BP1 and the progression of ovarian cancer, showing that loss of G3BP1 inhibits cell proliferation, migration, and invasion. Furthermore, the interaction between USP10 and G3BP1 was found, and they cooperate to promote tumor progression.
Review
Cell Biology
Youchaou Mobet, Xiaoyi Liu, Tao Liu, Jianhua Yu, Ping Yi
Summary: The methylation of adenosine in RNA to N6-methyladenosine (m(6)A) is involved in the regulation of metabolism in cancer cells. Dysregulation of m(6)A modification may lead to abnormalities in glucose, lipid, amino acid metabolism, and other metabolites, which can contribute to increased cell proliferation, tumor initiation, and metastasis. Understanding the role of m(6)A modification in metabolic reprogramming provides potential targets for cancer therapy and early detection.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Cell Biology
Jie Xu, Xiaoyi Liu, Yanjie Chen, Yuya Wang, Tao Liu, Ping Yi
Summary: This study identifies distinct m(5)C modification patterns in ovarian cancer patients, leading to metabolic heterogeneity, differences in chemotherapy sensitivity, and ultimately affecting overall survival.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Immunology
Yuya Wang, Yan Tang, Xianli Yang, Jie Xu, Yanjie Chen, Jing Xu, Shan Hu, Ping Yi
Summary: This study is the first to evaluate the ceRNA networks in placenta of patients with pregnancy-related intrahepatic cholestasis (ICP), and it shows that alterations in immune regulatory networks may impact fetal and placental growth. The findings suggest that ceRNA regulatory network may improve biomarker predictions for developing novel therapeutic approaches in ICP.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Yujiao Liu, Dan Yang, Tao Liu, Jianjun Chen, Jianhua Yu, Ping Yi
Summary: N6-methyladenosine (m6A) RNA methylation is the most common form of mRNA modification in eukaryotes, playing a crucial role in biological and biomedical research. This dynamic and reversible modification affects the fate of RNA molecules and is involved in various important biological processes. Dysregulation of m6A modification is linked to diseases, especially cancer. This review provides an overview of post-transcriptional and transcriptional regulatory mechanisms involving m6A modification and discusses its implications in disease development, as well as potential targets for therapeutics and diagnostics.
TRENDS IN MOLECULAR MEDICINE
(2023)
Review
Virology
Xiao Guo, Dongying Liu, Yukai Huang, Youcai Deng, Ying Wang, Jingrui Mao, Yuancheng Zhou, Yongai Xiong, Xinghong Gao
Summary: The mRNA vaccine technology has rapidly developed during the COVID-19 global pandemic. The COVID-19 mRNA vaccine plays a crucial role in preventing viral infection and also benefits the exploration and application of other viral mRNA vaccines. This review provides an overview of the optimization of mRNA vaccine development process, as well as the good immune efficacy and safety observed in clinical studies. Additionally, the important role of mRNA immunomodulators in treating viral diseases is briefly described.
Article
Chemistry, Multidisciplinary
Ya-fei Deng, Shu-ting Wu, Hong-yan Peng, Lei Tian, Ya-na Li, Yao Yang, Meng Meng, Lan-lan Huang, Pei-wen Xiong, Song-yang Li, Qing-lan Yang, Li-li Wang, Xiao-yao Li, Li-ping Li, Xiu-lan Lu, Xiao-hui Li, Yan-ling Wei, Zheng-hui Xiao, Jian-hua Yu, You-cai Deng
Summary: In this study, the researchers found that mTORC1 plays a critical role in the development and function of ILC3s, while mTORC2 is not essential. mTORC1 deficiency disrupts ILC3 heterogeneity and leads to differentiation into ILC1-like phenotypes. Furthermore, when mTORC1 activity is diminished, mTORC2 activity increases to protect ILC3s from severe loss and immune activity against intestinal infection.
ACTA PHARMACOLOGICA SINICA
(2023)
Review
Oncology
Shoubao Ma, Michael A. Caligiuri, Jianhua Yu
Summary: This review provides an in-depth analysis of the cross-talk between lung cancer TME and NK cells. The mechanisms used by TME to modulate NK cell phenotypes and limit infiltration, the role of TME in limiting NK cell antitumor activity, and the current challenges and obstacles hindering NK cell-based immunotherapy for lung cancer are highlighted. Potential opportunities and strategies to optimize NK cell-based immunotherapy for lung cancer are also discussed.
Review
Biochemistry & Molecular Biology
Guang He Ran, Yu Qing Lin, Lei Tian, Tao Zhang, Dong Mei Yan, Jian Hua Yu, You Cai Deng
Summary: Cell-intrinsic and cell-extrinsic factors, as well as the cellular microenvironment, play important roles in the homing and trafficking of NK cells, which are crucial for improving NK cell-based cancer immunotherapy.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Article
Multidisciplinary Sciences
Xu Cao, Jing Chen, Bolei Li, Jessica Dang, Wencan Zhang, Xiancai Zhong, Chongkai Wang, Mustafa Raoof, Zuoming Sun, Jianhua Yu, Marwan G. Fakih, Mingye Feng
Summary: This study identifies paclitaxel as a universal adjuvant that enhances the efficacy of antibody-dependent cellular phagocytosis (ADCP) in multiple cancers. The researchers found that paclitaxel polarizes macrophages and enhances their phagocytic ability, leading to increased ADCP of cancer cells. Furthermore, the down-regulation of CSF1R in macrophages enhances the ADCP of cancer cells. These findings suggest a potent strategy for using conventional anticancer drugs to stimulate macrophage phagocytosis and enhance the therapeutic efficacy of clinical anticancer antibodies.
